Verici Dx PLC Medicare National Payment Rate Confirmation
08 Janeiro 2024 - 4:00AM
RNS Non-Regulatory
TIDMVRCI
Verici Dx PLC
08 January 2024
Verici Dx plc
("Verici Dx" or the "Company")
Medicare National Payment Rate for Tutivia(TM) and Clarava(TM)
Effective as of January 1, 2024
CMS finalises gapfill median rate at $2,650 per test
Verici Dx plc (AIM: VRCI), a developer of advanced clinical
diagnostics for organ transplant, announces that the Centers for
Medicare & Medicaid Services ("CMS") released the Clinical
Laboratory Fee Schedule ("CLFS") payment rate of $2,650 established
through the "gapfill" process for both Tutivia(TM) (CPT 0320U), its
post-transplant test focused upon acute cellular rejection, and
Clarava(TM) (CPT 0319U), its pre-transplant prognosis test for the
risk of early acute rejection. This rate is effective as of January
1, 2024.
Having a national payment rate established by CMS represents a
step toward securing reimbursement for testing by Medicare, a
national health insurance program in the US that covers 63.9
million patients. Gapfill pricing is a method used by CMS to
establish a payment rate for clinical diagnostic laboratory tests
when no comparable test is priced on the CLFS and involves setting
the payment rate for the test at the median of rates established by
local Medicare contractors.
Sara Barrington, Chief Executive Officer of Verici Dx,
commented: "We are pleased that the pricing for both Tutivia(TM)
and Clarava(TM) has been confirmed and finalised at the proposed
rates. This is another important milestone in our strategy to
develop and commercialise a complementary suite of ground-breaking
products that offer end-to-end testing for kidney transplant
patients and their clinicians ."
Enquiries:
Verici Dx www.v ericidx .com
Sara Barrington, CEO Via Walbrook PR
Julian Baines, Chairman
Singer Capital Markets (Nominated Tel: 020 7496 3000
Adviser & Broker)
Aubrey Powell / Sam Butcher / Jalini
Kalaravy
Walbrook PR Limited Tel: 020 7933 8780 or vericidx@walbrookpr.com
Stephanie Cuthbert / Sam Allen Mob: 07796 794 663 / 07502 558 258
About Verici Dx plc www.vericidx.com
Verici Dx is a developer of a complementary suite of
leading-edge tests forming a kidney transplant platform for
personalised patient and organ response risk to assist clinicians
in medical management for improved patient outcomes. The underlying
technology is based upon artificial intelligence assisted
transcriptomic analysis to provide RNA signatures focused upon the
immune response and other biological pathway signals critical for
transplant prognosis of risk of injury, rejection and graft failure
from pre-transplant to late stage. The Company also has a mission
to accelerate the pace of innovation by research using the fully
characterised data from the underlying technology, including
through collaboration with medical device, biopharmaceutical and
data science partners.
The foundational research was driven by a deep understanding of
cell-mediated immunity and is enabled by access to expertly curated
collaborative studies in highly informative cohorts in kidney
transplant.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRADBGDBCXGDGSR
(END) Dow Jones Newswires
January 08, 2024 02:00 ET (07:00 GMT)
Verici Dx (LSE:VRCI)
Gráfico Histórico do Ativo
De Jul 2024 até Ago 2024
Verici Dx (LSE:VRCI)
Gráfico Histórico do Ativo
De Ago 2023 até Ago 2024